Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4199012 | 1.00 | CHRM1 (0.37) | CHRM1HTR2AMCHR1POLBMEN1 | |
| SCHEMBL10891765 | 0.87 | LTA4H (0.49) | LTA4H | |
| SCHEMBL23130390 | 0.74 | KDM1A (0.51) | CHRM1HTR2AMCHR1MEN1KMT2A | |
| SCHEMBL9639726 | 0.72 | MAPT (0.55) | MEN1KMT2ANPC1RAB9A | |
| SCHEMBL5289989 | 0.71 | LTA4H (0.50) | HTR2APOLBKMT2AMAN1B1LTA4H | |
| SCHEMBL9620214 | 0.70 | MAOA (0.39) | CHRM1HTR2AMCHR1MEN1KMT2A | |
| SCHEMBL4195898 | 0.69 | ALDH1A1 (0.39) | MEN1KMT2ANPC1RAB9A | |
| SCHEMBL4200940 | 0.69 | POLB (0.37) | POLBMEN1KMT2ALTA4HNPC1 | |
| SCHEMBL4195895 | 0.69 | ALDH1A1 (0.39) | MEN1KMT2ANPC1RAB9A | |
| SCHEMBL21565752 | 0.68 | POLB (0.47) | POLBLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389507-B2 | 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as TAAR-ligands | HOFFMANN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | claimed |
| CN-101765587-A | 2-azetidinemethanamines and 2-pyrrolidinemethanamines as TAAR ligands | HOFFMANN LA ROCHE | 2010-06-30 | — | — | CN | claimed |
| US-20090029962-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | HOFFMANN-LA ROCHE, INC. | 2009-01-29 | — | — | US | claimed |
| US-8389507-B2 | 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as TAAR-ligands | HOFFMANN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20130005988-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | GALLEY GUIDO (DE) | 2013-01-03 | — | — | US | disclosed |
| CN-101765587-A | 2-azetidinemethanamines and 2-pyrrolidinemethanamines as TAAR ligands | HOFFMANN LA ROCHE | 2010-06-30 | — | — | CN | disclosed |
| US-20090029962-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | HOFFMANN-LA ROCHE, INC. | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029962-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | TAAR1, TAAR5, NPY2R | CHRM1 136/4885HTR2A 13/4885MCHR1 14/4885 |
| US-20130005988-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | TAAR1, TAAR5, NPY2R | CHRM1 136/4885HTR2A 13/4885MCHR1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.